All treatment groups in Vertex Pharmaceuticals Inc.’s phase II study of the non-opioid VX-548 showed meaningful reductions in pain from baseline in treating diabetic peripheral neuropathy (DPN), pointing the company toward pivotal phase III studies and prompting analysts to applaud enthusiastically.
Bsense Bio Therapeutics Ltd. has nominated BSEN-760, a dual Kv7.2/3 and TRPV1 ion channel modulator, as a clinical candidate for the treatment of chronic pain.
Hangzhou Bio Sincerity Pharmaceutical Technology Co. Ltd. has identified histamine H3 receptor antagonists reported to be useful for the treatment of pain, attention deficit hyperactivity disorder, schizophrenia, epilepsy, sleep disorders, obesity, eating disorder, neuropathic pain and itching.
Artelo Biosciences Inc. has completed a pre-IND meeting with the FDA regarding the manufacturing, preclinical and clinical development plan for ART-26.12.
Researchers from China Pharmaceutical University and affiliated organizations have reported the discovery and preclinical evaluation of a novel bromodomain and extra-terminal (BET) inhibitor, DDO-8926, being developed for the management of neuropathic pain.
Researchers from Universita degli Studi di Pavia and affiliated organizations have presented the discovery of a novel sigma-1 receptor (S1R) antagonist, RC-752, being developed as an antinociceptive agent for the treatment of neuropathic pain.
After almost 30 years in business, Sangamo Therapeutics Inc. is finally nearing a BLA filing for one of its programs. But the company, wounded by the recent loss of alliances with Biogen Inc. and Novartis AG, is also running out of cash and investor interest – and it badly needs a new deal to stay afloat.
Researchers at Mossakowski Medical Research Centre at the Polish Academy of Sciences (PAS) and The University of Warsaw have divulged peptides reported to be useful for the treatment of pain.
Patients suffering from neuropathic pain, a chronic condition, have few treatment options and often develop tolerance to existing pain therapy that decreases its effectiveness. Now, a group of scientists from the University of Alabama at Birmingham (UAB) and the Baylor College of Medicine have described the pathophysiological mechanism of initiation, transmission and maintenance of neuropathic pain and identified a potential therapeutic target to treat it efficiently.
Confo Therapeutics NV is banking an up-front payment of $40 million from a licensing deal with Eli Lilly and Co. involving its lead asset, CFTX-1554, an oral inhibitor of the angiotensin II type 2 receptor, which is in phase I development for neuropathic pain. The deal includes up to $590 million more in potential milestones and tiered sales royalties. Ghent, Belgium-based Confo could also secure a further $590 million in additional milestones should Indianapolis-based Lilly elect to take forward an antibody-based inhibitor directed against the same target.
